MINNEAPOLIS, March 7, 2011 /PRNewswire/ — Uroplasty, Inc.
(Nasdaq:
UPI), a medical device company that develops, manufactures and
markets innovative proprietary products to treat voiding
dysfunctions, announced today that it will be presenting at the
ROTH Capital Partners 23rd Annual OC Growth Stock Conference on
Monday, March 14, 2011 at 8:30 am Pacific Time at the Ritz-Carlton
Laguna Nigel. David Kaysen, Uroplasty’s President and CEO, and Medi
Jiwani, Uroplasty’s Vice President and CFO, will discuss the
Company’s business strategy and historic financial results.
Attendance at the conference is by invitation only. A live audio
webcast of the presentation will be broadcast via the Internet.
Those interested in listening to the webcast may access it at
http://www.wsw.com/webcast/roth24/upi/
or through Uroplasty’s website at www.uroplasty.com. An archived
replay of the presentation will be available for 90 days.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with
wholly-owned subsidiaries in The Netherlands and the United
Kingdom, is a medical device company that develops, manufactures
and markets innovative proprietary products for the treatment of
voiding dysfunctions. Our focus is the continued commercialization
of our Urgent PC Neuromodulation System, the only FDA-cleared
system that delivers posterior tibial nerve stimulation (PTNS) for
the office-based treatment of overactive bladder and associated
symptoms of urgency, frequency and urge incontinence. We also offer
Macroplastique® Implants, an injectable urethral bulking agent
for the treatment of adult female stress urinary incontinence
primarily due to intrinsic sphincter deficiency. For more
information on the company and its products, please visit
Uroplasty, Inc.
‘/>”/>
